Therapies for Salivary Flux Stimulation in Patients Transplanted With Hematopoietic Stem Cells

Overview

The transplantation of hematopoietic stem cells (THSC) is a therapeutic modality developed for the treatment of various diseases such as leukemia, bone marrow aplasia, lymphomas, multiple myeloma, among others. Most patients who undergo the THSC usually have oral manifestations as a result of immunosuppression achieved by chemotherapy and/or radiotherapy. The most common complications are the reduction of salivary flow, mucositis and graft-versus-host disease (GVHD). These conditions can be very debilitating and interfere with medical therapy, leading to systemic complications, affecting the prognosis and increasing the length of hospitalization of the patient and the costs of treatment. To date, there is no protocol that prevents the reduction of salivary flow and minimizes the occurrence of mucositis and GVHD in these patients. This study aims to verify the effectiveness of treatment with two sialogogues (Hyperboloid and TENS [transcutaneous electrical stimulation]) to restore the flow and biochemical composition of saliva in patients undergoing THSC myeloablative and non-myeloablative conditionating regime.

Full Title of Study: “Effects of Mechanical and Electrical Sialogogues in Stimulation of the Flow and Biochemical Composition of Saliva in Patients Transplanted With Hematopoietic Stem Cells”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: Single (Investigator)
  • Study Primary Completion Date: June 2011

Detailed Description

It will be included in the sample a total of 60 patients undergoing hematopoietic stem cell transplantation (THSC) at the Clinical Hospital. Patients will be randomly divided into four groups, each with 15 subjects: group I patients who will use only the mechanical sialogogue; group II patients who will make use of electrical sialogogue (TENS); group III patients who will make use of mechanical sialogogue associated with TENS and group IV patients who will not receive therapy (control). The project will present the following experimental design: 1. Selection of patients to be subjected to the transplantation of hematopoietic stem cells; 2. Implementation of a reference sialometry; 3. Institution of therapy with mechanical and electrical sialogogue; 4. Clinical examination, assessment of the occurrence of mucositis and obtention of saliva samples pre- and post-THSC; 5. Qualitative analysis of saliva (turbidity, viscosity and color); 6. Biochemical analysis of saliva; 7. Statistical analysis of data.

Interventions

  • Device: mechanical stimulation (Elastomers)
    • The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
  • Procedure: TENS
    • transcutaneous electrical stimulation

Arms, Groups and Cohorts

  • Experimental: Elastomers
    • Patients will use hyperboloid as mechanical salivary stimuli. Patients will chew hyperboloid 3 times a day
  • Experimental: TENS
    • TENS is a eletric stimuli that will be use in the skin near to parotid glands. Patients will receive TENS treatment as eletric salivary stimuli. Patients will receive TENS stimuli once a day for 15 days
  • Experimental: Elastomers+TENS
    • Patients will receive TENS plus hyperboloid as eletric and mechanical treatment for salivary stimuli
  • No Intervention: No therapy (control)
    • Patients will not receive intervention

Clinical Trial Outcome Measures

Primary Measures

  • Salivary flux
    • Time Frame: 7 days

Participating in This Clinical Trial

Inclusion Criteria

  • Patients submitted to THSC at Clinical Hospital of Federal University who underwent a myeloablative or a non-myeloablative conditioning regime – Age over 16 years – Oral mucosa intact on the first day of conditioning – Ability to cooperate with treatment Exclusion Criteria:

  • Cases with no clinical follow up – Patients who refuse to participate – Patients with no ability to cooperate with treatment

Gender Eligibility: All

Minimum Age: 16 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Federal University of Minas Gerais
  • Collaborator
    • Tania Mara Pimenta Amaral
  • Provider of Information About this Clinical Study
    • Principal Investigator: Tarcilia Aparecida da Silva, Associate Professor – Federal University of Minas Gerais
  • Overall Official(s)
    • Tarcilia A Silva, PhD, Principal Investigator, Federal University of Minas Gerais

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.